NCT07147049

Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for moderate to severe acute pain after surgery.

Conditions

• Moderate to Severe Acute Postoperative Pain

Interventions

Type	Name	Description
DRUG	HL-1186	HL-1186 tablet for oral administration.
DRUG	HL-1186 placebo	HL-1186 placebo tablet for oral administration.

Timeline

• Start date: 2025-08-08
• Primary completion: 2025-12-01
• Completion: 2026-01-01
• First posted: 2025-08-28
• Last updated: 2025-12-22

Locations

1 site across 1 country: China